These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10735942)

  • 1. Measuring the activity of disease in cutaneous lupus erythematosus.
    Goodfield M
    Br J Dermatol; 2000 Mar; 142(3):399-400. PubMed ID: 10735942
    [No Abstract]   [Full Text] [Related]  

  • 2. A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients.
    Pons-Estel GJ; Quintana R; Alarcón GS; Sacnún M; Ugarte-Gil MF; Pons-Estel BA;
    Lupus; 2018 Sep; 27(10):1753-1754. PubMed ID: 29764291
    [No Abstract]   [Full Text] [Related]  

  • 3. Photoprotection awareness and practices among patients with systemic lupus erythematosus and its association with disease activity and severity.
    Abdul Kadir WD; Jamil A; Shaharir SS; Md Nor N; Abdul Gafor AH
    Lupus; 2018 Jul; 27(8):1287-1295. PubMed ID: 29665756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study.
    Niederkorn A; Frühauf J; Schwantzer G; Wutte N; Painsi C; Werner S; Stradner M; Berghold A; Hermann J; Aberer E
    Arch Dermatol Res; 2018 Aug; 310(6):485-493. PubMed ID: 29728857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lupus erythematosus and the skin: a journey at times perplexing, usually complex, often challenging, and evermore exhilarating.
    Obermoser G
    Lupus; 2010 Aug; 19(9):1009-11. PubMed ID: 20693193
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe visceral disease in subacute cutaneous lupus erythematosus.
    Weinstein CL; Littlejohn GO; Thomson NM; Hall S
    Arch Dermatol; 1987 May; 123(5):638-40. PubMed ID: 3579344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus.
    Cohen MR; Crosby D
    J Rheumatol; 1994 Sep; 21(9):1665-9. PubMed ID: 7799346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapies for cutaneous lupus erythematosus.
    Borucki R; Werth VP
    Cutis; 2020 Jun; 105(6):276-277. PubMed ID: 32716989
    [No Abstract]   [Full Text] [Related]  

  • 9. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus.
    Kuhn A; Meuth AM; Bein D; Amler S; Beissert S; Böhm M; Brehler R; Ehrchen J; Grundmann S; Haust M; Ruland V; Schiller M; Schulz P; Ständer S; Sauerland C; Köpcke W; Luger TA; Bonsmann G
    Br J Dermatol; 2010 Jul; 163(1):83-92. PubMed ID: 20394621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cutaneous-visceral interplay in patients with systemic lupus erythematosus].
    Potekhin NP; Filatova EA; Fursov AN; Glad'ko VV; Orlov FA
    Klin Med (Mosk); 2012; 90(7):51-5. PubMed ID: 23019977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
    Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
    Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus.
    Wieczorek IT; Propert KJ; Okawa J; Werth VP
    JAMA Dermatol; 2014 Mar; 150(3):291-6. PubMed ID: 24477339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.
    Klein RS; Morganroth PA; Werth VP
    Rheum Dis Clin North Am; 2010 Feb; 36(1):33-51, vii. PubMed ID: 20202590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters.
    Skiljevic D; Bonaci-Nikolic B; Brasanac D; Nikolic M
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):523-529. PubMed ID: 27557471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of patients' and physicians' assessments of disease activity using the Swedish version of the Systemic Lupus Activity Questionnaire.
    Pettersson S; Svenungsson E; Gustafsson J; Möller S; Gunnarsson I; Welin Henriksson E
    Scand J Rheumatol; 2017 Nov; 46(6):474-483. PubMed ID: 28293972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus.
    Grönhagen CM; Gunnarsson I; Svenungsson E; Nyberg F
    Lupus; 2010 Sep; 19(10):1187-94. PubMed ID: 20501526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-year retrospective review of bullous systemic lupus erythematosus in cutaneous and systemic lupus erythematosus patients.
    Chanprapaph K; Sawatwarakul S; Vachiramon V
    Lupus; 2017 Oct; 26(12):1278-1284. PubMed ID: 28358242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [What's new in internal medicine?].
    Bessis D
    Ann Dermatol Venereol; 2012 Dec; 139 Suppl 5():S194-201. PubMed ID: 23522706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus.
    Wenzel J; Zahn S; Bieber T; Tüting T
    Arch Dermatol Res; 2009 Jan; 301(1):83-6. PubMed ID: 18784932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The study of Cutaneous Lupus Erythematosus Disease Area and Severity Index in Indian patients with systemic lupus erythematosus.
    Salphale P; Danda D; Chandrashekar L; Peter D; Jayaseeli N; George R
    Lupus; 2011 Dec; 20(14):1510-7. PubMed ID: 21997966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.